The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
Open accessPublished version of a preprint
Abstract
B-RafV600E inhibitors have been suggested to promote tumor regression with the help of host immunity, but this hypothesis has not been examined directly in detail. In this study, we profiled immunologic changes in the tumor microenvironment and tumor-infiltrating lymphocytes (TIL) in a B-RafV600E/Pten-driven murine model of melanoma after administration of the B-RafV600E small molecule inhibitor PLX4720. In this model, we found that as tumors developed, they gradually acquired immunosuppressive features, including accumulation of regulatory T cells (Treg) and CD11b+/Gr-1+ myeloid cells and loss of Th1 effector functions on CD4+ TILs, such as CD40L and IFNγ expression. PLX4720 administration promoted development of a more immune stimulatory microenvironment associated with a relative increase in CD40L and IFNγ expression on intratumoral CD4+ TILs and a reduced accumulation of Tregs and CD11b+/Gr-1+ myeloid cells. Strikingly, CD40L or IFNγ blockade compromised the ability of PLX4720 to inhibit melanoma growth. Supporting this result, agonistic CD40 antibody was sufficient to evoke antitumor immunity and suppress tumor growth in tumor-bearing mice. Taken together, our results establish the critical role of immune-related changes, with key contributions for CD40L and IFNγ signaling in the antitumor responses triggered in vivo by B-RafV600E inhibitors. Cancer Res; 74(12); 3205–17. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We used a subcutaneously engrafted BRAFV600E melanoma model, which is clinically relevant and ICI-resistant23,24.”
From Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T. J., Mok, S., Cass, A. A., Haynes, N. M., Kinross, K. M., Yagita∥, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 274
RetractedExploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Self-citationCD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,706
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355
Self-citationMetabolic Regulation of T Lymphocytes
MacIver, N. J., Michalek, R. D., & Rathmell, J. C. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095956 · Cited by 1,244
Cited by
Sorted by citations
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ho, P.-C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.012 · Cited by 1,462
Self-citationTurning Cold into Hot: Firing up the Tumor Microenvironment
Duan, Q., Zhang, H., Zheng, J., & Zhang, L. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.022 · Cited by 934
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
Wang, H., Franco, F., Tsui, Y.-C., Xie, X., Trefny, M. P., Zappasodi, R., Mohmood, S. R., Fernández-García, J., Tsai, C.-H., Schulze, I., et al. (2020) · Nature Immunology · doi:10.1038/s41590-019-0589-5 · Cited by 694
Self-citationThe multifaceted role of CD4+ T cells in CD8+ T cell memory
Laidlaw, B. J., Craft, J. E., & Kaech, S. M. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.10 · Cited by 657
Self-citationDisturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion
Yu, Y.-R., Imrichova, H., Wang, H., Chao, T., Xiao, Z., Gao, M., Rincon-Restrepo, M., Franco, F., Genolet, R., Cheng, W.-C., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0793-3 · Cited by 593
Self-citationRegulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P., & Verdeil, G. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.80 · Cited by 570
Self-citationMetabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
Kishton, R. J., Sukumar, M., & Restifo, N. P. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.016 · Cited by 548
Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis
Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0672 · Cited by 459
Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459
Targeting T cell metabolism for therapy
O’Sullivan, D., & Pearce, E. L. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.004 · Cited by 261
Ascierto, P. A., Mandalà, M., Ferrucci, P. F., Guidoboni, M., Rutkowski, P. L., Ferraresi, V., Arance, A. M., Guida, M., Maiello, E., Gogas, H. J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02961 · Cited by 255
Liu, P.-S., Chen, Y.-T., Li, X., Hsueh, P., Tzeng, S., Chen, H., Shi, P.-Z., Xie, X., Parik, S., Planque, M., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01430-3 · Cited by 243
Self-citationMansurov, A., Ishihara, J., Hosseinchi, P., Potin, L., Marchell, T. M., Ishihara, A., Williford, J., Alpar, A. T., Raczy, M. M., Gray, L. T., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0549-2 · Cited by 230
Peske, J. D., Thompson, E. D., Gemta, L. F., Baylis, R. A., Fu, Y., & Engelhard, V. H. (2015) · Nature Communications · doi:10.1038/ncomms8114 · Cited by 227
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Conza, G. D., Tsai, C.-H., Gallart‐Ayala, H., Yu, Y.-R., Franco, F., Zaffalon, L., Xie, X., Li, X., Xiao, Z., Raines, L. N., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01047-4 · Cited by 216
Self-citationBRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
Proietti, I., Skroza, N., Michelini, S., Mambrin, A., Balduzzi, V., Bernardini, N., Marchesiello, A., Tolino, E., Volpe, S., Maddalena, P., et al. (2020) · Cancers · doi:10.3390/cancers12071823 · Cited by 192
Immunological Mechanisms Underneath the Efficacy of Cancer Therapy
Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0197 · Cited by 175
Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity
Perry, C. J., Muñoz-Rojas, A. R., Meeth, K. M., Kellman, L. N., Amezquita, R. A., Thakral, D., Du, V. Y., Wang, J. X., Damsky, W., Kuhlmann, A., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171435 · Cited by 167
Self-citationTargeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 162
Lal, N., White, B. S., Goussous, G., Pickles, O. J., Mason, M. J., Beggs, A. D., Tanière, P., Willcox, B. E., Guinney, J., & Middleton, G. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1090 · Cited by 158
The Influence of Tumor Microenvironment on Immune Escape of Melanoma
Simiczyjew, A., Dratkiewicz, E., Mazurkiewicz, J., Ziętek, M., Matkowski, R., & Nowak, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218359 · Cited by 157
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
Coffelt, S. B., & de Visser, K. E. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.006 · Cited by 147
Pelster, M. S., & Amaria, R. N. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919830826 · Cited by 137
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
Kuske, M., Westphal, D., Wehner, R., Schmitz, M., Beissert, S., Praetorius, C., & Meier, F. E. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.019 · Cited by 131
Kaartinen, T., Luostarinen, A., Maliniemi, P., Keto, J., Arvas, M., Belt, H., Koponen, J., Loskog, A., Mustjoki, S. M., Porkka, K., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.03.067 · Cited by 126
Predictive biomarkers for response to immune checkpoint inhibition
Shum, B., Larkin, J., & Turajlic, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.036 · Cited by 118
Immunoediting instructs tumor metabolic reprogramming to support immune evasion
Tsai, C., Chuang, Y., Li, X., Yu, Y.-R., Tzeng, S., Teoh, S. T., Lindblad, K. E., Matteo, M. D., Cheng, W.-C., Hsueh, P., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.12.003 · Cited by 116
Self-citationImmunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
Li, L., Zhang, F., Liu, Z., & Fan, Z. (2023) · Cancers · doi:10.3390/cancers15010321 · Cited by 123
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Griffin, M., Scotto, D., Josephs, D. H., Mele, S., Crescioli, S., Bax, H. J., Pellizzari, G., Wynne, M. D., Nakamura, M., Hoffmann, R. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19836 · Cited by 120
Kurt, F. G. Ö., Lasser, S., Arkhypov, I., Utikal, J. S., & Umansky, V. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170762 · Cited by 111
Zhang, Z., Richmond, A. J., & Yan, C. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137353 · Cited by 107
Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis
Shabaneh, T. B., Molodtsov, A. K., Steinberg, S. M., Zhang, P., Torres, G. M., Mohamed, G. A., Boni, A., Curiel, T. J., Angeles, C. V., & Turk, M. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0365 · Cited by 110
Steinberg, S. M., Shabaneh, T. B., Zhang, P., Martyanov, V., Li, Z., Malik, B. T., Wood, T. A., Boni, A., Molodtsov, A. K., Angeles, C. V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1755 · Cited by 102
Huang, Z. D., Gan, J., Long, Z., Guo, G., Shi, X., Wang, C., Zang, Y., Ding, Z., Chen, J., Zhang, J., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.009 · Cited by 98
Ascierto, P. A., Casula, M., Bulgarelli, J., Pisano, M., Piccinini, C., Piccin, L., Cossu, A., Mandalà, M., Ferrucci, P. F., Guidoboni, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44475-6 · Cited by 102
Phelps, C. M., Willis, N. B., Duan, T., Lee, A. H., Zhang, Y., Rodriguez J, D. M., Pandey, S. P., Laughlin, C. R., Rosen, A. B. I., McPherson, A. C., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.018 · Cited by 91
Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma
Ilieva, K. M., Corrêa, I., Josephs, D. H., Karagiannis, P., Egbuniwe, I. U., Cafferkey, M., Spicer, J. F., Harries, M., Nestle, F. O., Lacy, K. E., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0290 · Cited by 91
Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma
Dummer, R., Ascierto, P. A., Nathan, P., Robert, C., & Schadendorf, D. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4401 · Cited by 81
Targeted Therapy and Immunosuppression in the Tumor Microenvironment
Allegrezza, M. J., & Conejo-Garcia, J. R. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.11.009 · Cited by 80
Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle
Cheng, W.-C., Tsui, Y., Ragusa, S., Koelzer, V. H., Mina, M., Franco, F., Laubli, H. P., Tschumi, B., Speiser, D. E., Romero, P. J., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0290-0 · Cited by 77
Self-citationThe multifaceted anti-cancer effects of BRAF-inhibitors
Croce, L., Coperchini, F., Magri, F., Chiovato, L., & Rotondi, M. (2019) · Oncotarget · doi:10.18632/oncotarget.27304 · Cited by 75
The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy
Neophytou, C. M., Pierides, C., Christodoulou, M., Costeas, P., Kyriakou, T.-C., & Papageorgis, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00899 · Cited by 75
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors
Glen, C., Tan, Y. Y., Waterston, A. M., Evans, T. R. J., Jones, R. J., Petrie, M. C., & Lang, N. N. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.01.096 · Cited by 77
Missiaen, R., Lesner, N. P., & Simon, M. C. (2023) · The EMBO Journal · doi:10.15252/embj.2022112067 · Cited by 78
BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma
Steinberg, S. M., Zhang, P., Malik, B. T., Boni, A., Shabaneh, T. B., Byrne, K. T., Mullins, D. W., Brinckerhoff, C., Ernstoff, M. S., Bosenberg, M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0074 · Cited by 69
Self-citationThe tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities
Kung, H., Zheng, K., Zimmerman, J. W., & Zheng, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01077-z · Cited by 86
Middleton, G., Yang, Y., Campbell, C. D., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3579 · Cited by 63
Reddy, S. M., Reuben, A., & Wargo, J. A. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0531-z · Cited by 61
Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries
Ho, P., & Kaech, S. M. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.04.003 · Cited by 62
Self-citationMiddleton, G., Robbins, H. L., André, F., & Swanton, C. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.11.004 · Cited by 59
Şahin, İ. H., Goyal, S., Pumpalova, Y. S., Sonbol, M. B., Das, S., Haraldsdóttir, S., Ahn, D. H., Ciombor, K. K., Chen, Z., Draper, A., et al. (2021) · The Oncologist · doi:10.1002/onco.13741 · Cited by 45
Mouse Models of Tumor Immunotherapy
Ngiow, S. F., Loi, S., Thomas, D. M., & Smyth, M. J. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.004 · Cited by 44
Ngiow, S. F., Meeth, K. M., Stannard, K. A., Barkauskas, D. S., Bollag, G. E., Bosenberg, M., & Smyth, M. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1089381 · Cited by 43
Self-citationBRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition
Moujaber, T., Etemadmoghadam, D., Kennedy, C. J., Chiew, Y.-E., Balleine, R. L., Saunders, C. A. B., Wain, G., Gao, B., Hogg, R. J., Srirangan, S., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00221 · Cited by 41
Engineered E. coli Nissle 1917 for delivery of bioactive IL-2 for cancer immunotherapy
Tumas, S., Meldgaard, T. S., Vaaben, T. H., Hernandez, S. S., Rasmussen, A. T., Vazquez-Uribe, R., Hadrup, S. R., & Sommer, M. O. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-39365-2 · Cited by 44
Malignant melanoma—The cradle of anti-neoplastic immunotherapy
Koller, K. M., Wang, W., Schell, T. D., Cozza, E. M., Kokolus, K. M., Neves, R. I., Mackley, H. B., Pameijer, C. R., Leung, A. M., Anderson, B. E., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.010 · Cited by 40
Phadke, M. S., Chen, Z., Li, J., Mohamed, E. T., Davies, M. A., Smalley, I., Duckett, D. R., Palve, V. C., Czerniecki, B. J., Forsyth, P. A., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0905 · Cited by 40
Luo, M., Xia, Y., Wang, F., Zhang, H., Su, D., Su, C., Yang, C., Wu, S., An, S., Lin, S., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.010 · Cited by 40
Kouidhi, S., Noman, M. Z., Kiéda, C., Elgaaïed, A. B., & Chouaïb, S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00114 · Cited by 39
Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma
Ziogas, D. C., Konstantinou, F., Bouros, S., Theochari, M., & Gogas, H. J. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00593-9 · Cited by 36
The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
Stege, H. M., Haist, M., Nikfarjam, U., Schultheis, M., Heinz, J., Pemler, S., Loquai, C., & Grabbe, S. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00840-3 · Cited by 35
Ayeni, D. O., Miller, B., Kuhlmann, A., Ho, P., Robles-Oteíza, C., Gaefele, M., Levy, S., de Miguel, F. J., Perry, C. J., Guan, T., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0643-8 · Cited by 32
Self-citationThe future of targeted kinase inhibitors in melanoma
Caksa, S., Baqai, U., & Aplin, A. E. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108200 · Cited by 37
Mechanisms of Resistance to Immune Checkpoint Antibodies
Ramos, R. N., Piaggio, E., & Romano, E. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_11 · Cited by 32
Bellmann, L., Cappellano, G., Schachtl‐Riess, J. F., Prokopi, N., Seretis, A., Ortner, D., Tripp, C. H., Brinckerhoff, C., Mullins, D. W., & Stoitzner, P. (2019) · International Journal of Cancer · doi:10.1002/ijc.32777 · Cited by 33
Wyluda, E., Cheng, J., Schell, T. D., Haley, J. S., Mallon, C. A., Neves, R. I., Robertson, G. P., Sivik, J. M., Mackley, H. B., Talamo, G., et al. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1026507 · Cited by 29
Zimmer, L., Livingstone, E., Krackhardt, A. M., Schultz, E. S., Göppner, D., Assaf, C., Trebing, D., Stelter, K., Windemuth-Kieselbach, C., Ugurel, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.011 · Cited by 27
Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest
Acquavella, N., Clever, D. C., Yu, Z., Parker, M. R., Palmer, D. C., Xi, L., Pflicke, H., Ji, Y., Gros, A., Hanada, K., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0122 · Cited by 27
Self-citationLeick, K. M., Pinczewski, J., Mauldin, I. S., Young, S. J., Deacon, D. H., Woods, A. N., Bosenberg, M., Engelhard, V. H., & Slingluff, C. L. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02345-5 · Cited by 25
Self-citationJung, T., Haist, M., Kuske, M., Grabbe, S., & Bros, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189890 · Cited by 26
Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
Dixon-Douglas, J. R., Patel, R. P., Somasundram, P. M., & McArthur, G. A. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01243-x · Cited by 30
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
Peiffer, L., Farahpour, F., Sriram, A., Spassova, I., Hoffmann, D. E., Kubat, L., Stoitzner, P., Gambichler, T., Sucker, A., Ugurel, S., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02804-4 · Cited by 25
Isazadeh, A., Hajazimian, S., Garshasbi, H., Shadman, B., Baghbanzadeh, A., Chavoshi, R., Taefehshokr, S., Jadid, M. F. S., Hajiasgharzadeh, K., & Baradaran, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29905 · Cited by 23
Regulatory T cells in the immunotherapy of melanoma
Ouyang, Z., Wu, H., Li, L., Luo, Y., Li, X., & Huang, G. (2015) · Tumor Biology · doi:10.1007/s13277-015-4315-0 · Cited by 22
Haist, M., Stege, H. M., Kuske, M., Bauer, J., Klumpp, A., Grabbe, S., & Bros, M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10097-z · Cited by 24
Advances in tumor-associated macrophage-mediated chemotherapeutic resistance in glioma
Liu, X., & Yu, Q. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1676338 · Cited by 21
BRAF inhibitors and their immunological effects in malignant melanoma
Adams, R., Coumbe, J. E. M., Coumbe, B. G. T., Thomas, J., Willsmore, Z., Dimitrievska, M., Yasuzawa-Parker, M., Hoyle, M., Ingar, S., Geh, J. L. C., et al. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2044796 · Cited by 18
Zhang, M.-J., Liang, M., Yang, S., Ma, X., Wan, S., Yang, Q., Wang, S., Xu, Z., & Sun, Z. (2023) · Chemical Communications · doi:10.1039/d2cc05498a · Cited by 18
Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition
Guardamagna, M., Berciano‐Guerrero, M., González, B. V., Pérez-Ruiz, E., Oliver, J., Lavado-Valenzuela, R., Rueda‐Domínguez, A., Barragán, I., & Queipo‐Ortuño, M. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911990 · Cited by 17
Krykbaeva, I., Bridges, K., Damsky, W., Pizzurro, G. A., Alexander, A. F., McGeary, M. K., Park, K., Muthusamy, V., Eyles, J. E., Luheshi, N., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0699 · Cited by 18
Self-citationEfficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review
Rizzetto, G., SIMONI, E. D., Molinelli, E., Offidani, A., & Simonetti, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512383 · Cited by 17
Guan, R., Lyu, Q., Lin, A., Liang, J., Ding, W., Cao, M., Luo, P., & Zhang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670927 · Cited by 16
Wen, J., Qin, Y., Li, C., Dai, X., Wu, T., & Yin, W. (2020) · AMB Express · doi:10.1186/s13568-020-0949-4 · Cited by 14
Pickles, O. J., Drozd, A., Tee, L. J., Beggs, A. D., & Middleton, G. (2020) · Oncotarget · doi:10.18632/oncotarget.27681 · Cited by 13
Bahrambeigi, S., Sanajou, D., & Shafiei‐Irannejad, V. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.06.008 · Cited by 11
Park, R., da Silva, L. L., Lee, S., Riaño, I., & Saeed, A. (2021) · Future Oncology · doi:10.2217/fon-2021-0552 · Cited by 12
White, M. G., Sloane, R. A. S., Witt, R. G., Reuben, A., Gaudreau, P. O., Andrews, M. C., Feng, N., Johnson, S. B., Class, C. A., Bristow, C. A., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1992880 · Cited by 12
Ramos-Ramírez, M., Caballé‐Perez, E., Lucio-Lozada, J., Romero-Núñez, E., Castillo-Ruiz, C., Dorantes-Sánchez, L., Flores‐Estrada, D., Recondo, G., Barrios‐Bernal, P., Cabrera-Miranda, L. A., et al. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10245-7 · Cited by 12
Rogala, P., Czarnecka, A. M., Cybulska-Stopa, B., Ostaszewski, K., Piejko, K., Ziętek, M., Dziura, R., Rutkowska, E., Galus, Ł., Kempa-Kamińska, N., et al. (2022) · Cancers · doi:10.3390/cancers14092123 · Cited by 10
Nakamura, K., Yaguchi, T., Murata, M., Ota, Y., Mikoshiba, A., Kiniwa, Y., Okuyama, R., & Kawakami, Y. (2024) · Cancer Science · doi:10.1111/cas.16251 · Cited by 10
PD-1 Expression and Function of T-Cell Subsets in TILs From Human Lung Cancer
Gu, Y., Sheng, S. Y., Tang, Y., Lu, C. G., Zou, J. Y., Wang, Y. F., & Hong, H. Y. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000292 · Cited by 10
Immunomodulation of human T cells by microbubble-mediated focused ultrasound
Baez, A. G., Singh, D., He, S., Hajiaghayi, M., Gholizadeh, F., Darlington, P. J., & Helfield, B. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1486744 · Cited by 9
Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
Shaikh, S. S., Zang, Y., Hanmer, J., Wang, H., Lin, Y., Davar, D., Zarour, H. M., Kirkwood, J. M., & Najjar, Y. G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1022496 · Cited by 9
Hornsteiner, F., Vierthaler, J., Strandt, H., Resag, A., Fu, Z., Außerhofer, M., Tripp, C. H., Dieckmann, S. M., Kanduth, M., Farrand, K. J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008606 · Cited by 10
BRAF-inhibition and tumor immune suppression
Steinberg, S. M., & Turk, M. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.988039 · Cited by 8
MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer
Xie, M., Zheng, H., Madan-Lala, R., Dai, W., Gimbrone, N. T., Chen, Z., Kinose, F., Blackstone, S. A., Smalley, K. S. M., Cress, W. D., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0698 · Cited by 9
He, S., Xu, J., & Wu, J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107097 · Cited by 8
Kahn, A. M., Perry, C. J., Etts, K., Kluger, H. M., & Sznol, M. (2023) · The Oncologist · doi:10.1093/oncolo/oyad300 · Cited by 8
Metadata
- Authors
- Ho, P.-C., Meeth, K. M., Tsui, Y.-C., Srivastava, B., Bosenberg, M. W., & Kaech, S. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Corresponding author
- Kaech, Susan M.
- Venue
- Cancer Research
- Published
- 2014-06-12
- Volume
- 74
- Issue
- 12
- Pages
- 3205-3217
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC4063281
- OpenAlex
- W1974056979
- Cited by
- 126
- References
- 53
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 4 · 2023: 16 · 2022: 15 · 2021: 15 · 2020: 19 · 2019: 10 · 2018: 4 · 2017: 7 · 2016: 9 · 2015: 12 · 2014: 5
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Yale University
- National Cancer Institute (P50CA121974, P30CA016359)
- National Institute of Allergy and Infectious Diseases (R01AI074699)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- BRAF V600E inhibitors, PLX4720, melanoma, tumor microenvironment, tumor-infiltrating lymphocytes, CD40 ligand, interferon-gamma, regulatory T cells, myeloid cells, antitumor immunity, immune checkpoint blockade, PTEN
- MeSH terms
- Animals, Antigen-Presenting Cells, Antineoplastic Agents, Drug Screening Assays, Antitumor, Indoles, Interferon-gamma, Macrophages, Melanoma, Experimental, Mice, Transgenic, Skin Neoplasms, Sulfonamides, Signal Transduction, CD4-Positive T-Lymphocytes, Mutation, Missense, CD40 Ligand, Proto-Oncogene Proteins B-raf, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
